AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03959280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Description: * The exercise program consists of 2 x 1.5-hour supervised nordic walking sessions weekly during 12 weeks and 1-hour unsupervised moderate physical activity per week from week 4.~* The diet intervention includes one face-to-face consultation with a dietician and one telephone-based contact monthly, i.e. 6 diet interventions for 12 weeks.~* Behavioural changes techniques will be included in diet and exercise interventions.
Study NCT03959280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This intervention will include tailored instruction on CPAP use and standard advices on physical activity and nutrition at CPAP initiation.
Study NCT02163018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAL-MPE1
Description: Subcutaneous administration of increasing doses of HAL-MPE1
Study NCT02735135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENTRY 1200 for 1 month
Description: The patient is placed on a SENTRY 1200 mattress for 1 month.
Study NCT02735135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENTRY 1200 for 1 day
Description: The patient is placed on a SENTRY 1200 mattress for 1 day.
Study NCT02735135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIRSOFT DUO for 1 month
Description: The patient is placed on an AIRSOFT DUO mattress for 1 month.
Study NCT01542567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abitren
Description: SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
Study NCT01542567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suppositories
Study NCT00802113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 x 5 days
Study NCT02163018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration of increasing doses of placebo
Study NCT03529292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmeaCell
Description: Lipoaspirate obtained from liposuction is treated by the AmeaCell® device in order to obtain Matrix and Cells which contains cellular phase and matrix phase. The Matrix ancd Cells are injected in the same patient as facial wrinkles filler.
Study NCT01022190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib (Arcoxia)
Description: Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days
Study NCT03979092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IP-ACLS
Description: Three senior consultants and 12 trainers conduct 2-day IP-ACLS training.~1. Pre-class activities: preparation First exposure reading on provider manual and lecturer notes about a new knowledge of ACLS to enhance self-directed learning.~2. Interactive lecture sessions: 10 topics Interactive lectures (15-20 minutes per topic) introduce a new knowledge, which anchor to their existing knowledge according to ACLS algorithms.~3. Simulation sessions: 10 sessions Skill sessions (50 minutes per session) used high-fidelity simulation mannequin in a team approach. Students learn through role-playing with different practical scenarios. Experiential learning is focused on hands-on and collaborative strategies for enhancing a deeper learning.~4. Debriefing: feedback and reflection Trainers provide immediate feedback and discussion throughout the scenarios. Debriefing is focused on the positive aspect and areas for improvement.
Study NCT03979092 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist
Description: Waitlist group will participate in subsequent IP-ACLS training.
Study NCT01903837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan (Low Dose)
Description: Tablets taken once daily
Study NCT01903837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan (Medium Dose)
Description: Tablets taken once daily
Study NCT01903837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan (High Dose)
Description: Tablets taken once daily
Study NCT01903837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets taken once daily
Study NCT01903837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Tablets taken once daily
Study NCT01903837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Tablets taken once daily
Study NCT00835471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib plus docetaxel or pemetrexed
Description: non-squamous carcinoma: pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16, every 21 days. Pemetrexed will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.~squamous carcinoma: Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days. Docetaxel will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.
Study NCT00835471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: erlotinib 150 mg/day continuously until disease progression
Study NCT00244023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: one sachet of 50 mg applied once a day, possibly titrated to two sachets if insufficient improvement of erectile function
Study NCT00244023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: testosterone gel, one sachet of 50 mg applied once a day, possibly titrated to 100 mg if insufficient effect
Study NCT00244023 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: one sachet of placebo gel once a day possibly titrated to 2 sachets if insufficient efficacy
Study NCT03413020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: proton pump inhibitor
Study NCT03413020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bismuth Potassium Citrate
Description: gastric mucosal protective drug with anti-H. pylori effect
Study NCT03413020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: antibiotic for H. pylori eradication
Study NCT03413020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: antibiotic for H. pylori eradication
Study NCT03413020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Description: antibiotic for H. pylori eradication
Study NCT03413020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin
Description: antibiotic for H. pylori eradication
Study NCT02011009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV seropositive patients
Description: During a routine visit, a self-administered anal swab will be proposed as well as an anonymous questionnaire about sexual practices. In addition to usual outpatient treatment an examination and an evaluation of a possible sexually transmitted infection (STI) will be realized. Some questions about risk factors traditionally associated with carriage of resistant bacteria will also be investigated with the aid of the questionnaire such as: use of antibiotics during the year, travel in areas at risk.
Study NCT01937650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy plus metronidazole
Description: Metronidazole was added to the standard radiotherapy that is routinely used.
Study NCT02595190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacral canal cyst microscopic tamponade
Description: sacral canal cyst microscopic tamponade treatment
Study NCT02595190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin + tramadol
Description: dose range：gabapentin 400-1200mg tid, tramadol 100-200mg bid
Study NCT02595190 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: resting state functional magnetic resonance imaging (rfMRI)
Description: First time:2 days before Surgery or Drug use; Second time:3 months after Surgery or Drug use; Third time:1 year after Surgery or Drug use
Study NCT02595190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resting state functional magnetic resonance imaging (rfMRI)
Description: First time:2 days before Surgery or Drug use; Second time:3 months after Surgery or Drug use; Third time:1 year after Surgery or Drug use
Study NCT00802113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 3.2 mg/kg/day x 2 days
Study NCT00802113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days
Study NCT03663400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GWAS analysis by Illumina BeadChip
Description: will generate comprehensive genotype data for patients. Samples will be used for transcriptional profiling, microbiota profiling by 16S analysis and immunological profiling by flow cytometry
Study NCT03354507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate. See arms.
Study NCT02280798 — intervention group
Intervention type: PROCEDURE
Intervention: Endometrial Biopsy
Description: 4 endometrial biopsy
Study NCT02062658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5mg/kg IV
Study NCT02062658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention
Description: A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.
Study NCT02164422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine 3mg/day
Description: 3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
Study NCT02164422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine 1.5mg/day
Description: 1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
Study NCT02164422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00857870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.~Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.~After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose.
Study NCT00857870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of \<5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.
Study NCT00271323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin
Description: Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
Study NCT00271323 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
Study NCT01061450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 80 mg once a day
Study NCT01061450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill once a day
Study NCT01857869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK257049 Dosage 1
Description: RTS,S/AS01B administered as 0.5 mL dose at 0 and 1 months and 0.1 mL dose at 7 months for 0,1,7 M Group (delayed fractional dose group). In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
Study NCT01857869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK257049 Dosage 2
Description: RTS,S/AS01B administered as three doses of 0.5mL given one month apart (0, 1, 2 M group) in the challenge model. In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
Study NCT01857869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sporozoite-infected mosquitoes challenge
Description: Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the volunteers. For each volunteer, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored.~The challenge is scheduled to occur approximately 21 days (3 weeks) after the last vaccination visit (Study Day 196). Volunteers who reconsent for the boost/rechallenge phase will be rechallenged with sporozoite-infected mosquitoes, scheduled to occur approximately 21 days (3 weeks) after the booster dose (Booster Phase Study Day 21).
Study NCT02882295 — intervention group
Intervention type: OTHER
Intervention: Validation of a handwriting scale
Study NCT02164656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness for smokers
Study NCT02475655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 10 mg orally twice daily for 5 weeks
Study NCT01972893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYD1
Description: Plan I - Tablet ZYD1 - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet ZYD1 - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet ZYD1 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I.
Study NCT01972893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Plan I - Tablet Placebo - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet Placebo - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet Placebo 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I.
Study NCT03382847 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transplant with HCV positive donor, followed by surveillance and treatment of viremia
Description: Heart transplant with HCV positive donor, followed by treatment for viremia if viremia occurs
Study NCT03371797 — intervention group
Intervention type: DRUG
Intervention: Valsartan, Amlodipine -
Description: Valsartan is a non-peptide, orally active, and specific angiotensin II receptor blocker acting on the AT1 receptor subtype used as an antihypertensive agent.~Amlodipine besylate is a dihydropyridine long-acting calcium channel blocker.
Study NCT03130790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlitinib
Description: 300mg, oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Study NCT03130790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Study NCT03130790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Study NCT03130790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mFOLFOX6
Description: concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Study NCT02893579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early SR intervention
Description: Self-directed stress reduction program delivered through a smart-phone application
Study NCT02893579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed SR intervention
Description: Activity tracking only for the first month
Study NCT01256190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrocaps (fibrin sealant)
Description: human thrombin and fibrinogen topical powder
Study NCT01256190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelatin sponge
Description: absorbable gelatin sponge for topical use
Study NCT01256190 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge
Description: absorbable gelatin sponge for topical use
Study NCT02936661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT02936661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00659347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOV 21, 947
Description: Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
Study NCT00659347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules,25 mg,BID,6weeks
Study NCT03596541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart and Respiratory Auscultation of an open real-time tele-stethoscopy system (EHAS-Fundatel digital stethoscope)
Description: We compare the respiratory and heart auscultation of clinicians using the EHAS-Fundatel digital stethoscope and a conventional stethoscope and we will observe; inter-observer and intra-observer differences by two auscultation methods.
Study NCT03596541 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heart and Respiratory Auscultation of an open real-time tele-stethoscopy system (EHAS-Fundatel digital stethoscope)
Description: We compare the respiratory and heart auscultation of clinicians using the EHAS-Fundatel digital stethoscope and a conventional stethoscope and we will observe; inter-observer and intra-observer differences by two auscultation methods.
Study NCT02065427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support.
Study NCT04328207 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Financial Incentive
Description: Standard of care eye health education
Study NCT04328207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Patients who are referred for an in-person follow-up exam will receive a financial incentive once the referral visit is completed.
Study NCT02855541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeskCycle
Description: A small cycling ergometer that can fit under a desk at the workplace.
Study NCT02482675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
Study NCT02482675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose with Non-fat Milk
Description: Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
Study NCT02482675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose with Whey Protein Isolate
Description: Following baseline measurements, participants will consume 75 g glucose and whey protein isolate dissolved in 2 cups water within five minutes.
Study NCT02482675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose with Sodium Caseinate
Description: Following baseline measurements, participants will consume 75 g glucose and sodium caseinate dissolved in 2 cups water within five minutes.